SSA
EBACU

Schonfeld Strategic Advisors’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EBACU Stock Details EBACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-89,475
Closed -$888K – 2710
2021
Q3 		$888K Sell
89,475
-27,018
-23% -$268K 0.01% 1005
2021
Q2 		$1.16M Sell
116,493
-293,507
-72% -$2.94M 0.01% 877
2021
Q1 		$4.13M Buy
+410,000
New +$4.1M 0.05% 482

Other funds holding EBACU

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Schonfeld Strategic Advisors's EBACU Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of European Biotech Acquisition Corp. Units (EBACU) in Q4 2021, closing a stake of 89,475 shares — an estimated $888K sold.

Schonfeld Strategic Advisors first reported a position in EBACU in Q1 2021 and held it in 3 quarters. The position peaked at $4.13M in Q1 2021. 26 funds tracked by Wall St. Rank hold EBACU as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining European Biotech Acquisition Corp. Units position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 89,475 European Biotech Acquisition Corp. Units shares in Q4 2021, an estimated $888K.
  • Schonfeld Strategic Advisors first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's European Biotech Acquisition Corp. Units position peaked at $4.13M in Q1 2021.
  • 26 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.